15.3 C
New York
Friday, September 29, 2023

This Is Too Hot For Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Crinetics Pharmaceuticals Inc. (CRNX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 0.07%, to $28.65. The Crinetics Pharmaceuticals Inc. has recorded 12,653 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.

Sponsored

Stocks Info

As a NASDAQ listed company, CRNX falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $28.63 and fluctuated between $29.49 as its day high and $28.60 as its day low. The current market capitalization of Crinetics Pharmaceuticals Inc. is $1.55B. A total of 1.72 million shares were traded on the day, compared to an average of 1.25M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CRNX has seen 2 BUY and 5 SELL insider trades, representing the acquisition of 30,000 and the disposition of 80,922 shares. Over the last 12 months, there were 22 BUYs and 23 SELLs from insiders. Insiders purchased 279,281 shares during that period but sold 189,870.

In the most recent transaction, Struthers Richard Scott sold 14,157 shares of CRNX for 20.35 per share on Jul 13. After the transaction, the President & CEO now owns 630,805 company shares. In a previous transaction on Jul 12, Struthers Richard Scott sold 11,459 shares at 20.17 per share. CRNX shares that President & CEO owns now total 644,962.

Among the insiders who sold shares, Struthers Richard Scott disposed of 24,384 shares on Jul 11 at a per-share price of $20.14. This resulted in the President & CEO holding 656,421 shares of CRNX after the transaction. In another insider transaction, Wilson Marc sold 30,922 shares at $19.97 per share on Jun 20. Company shares held by the CFO now total 95,158.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CRNX in the last 3 months, the mean price target is $48.50 with high estimates of $60.00 and low estimates of $33.00. In terms of 52-week highs and lows, CRNX has a high of $31.00 and a low of $15.23.

As of this writing, CRNX has an earnings estimate of -$0.91 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.74 per share and a lower estimate of -$1.02. The company reported an EPS of -$0.85 in the last quarter, which was -4.90% lower than expectations of -$0.81.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $4.68, while its Total Shareholder’s Equity was $331.94M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 5.00.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles